At Dana-Farber Cancer Institute, basic, translational, clinical, and population sciences research are never far apart — physically or philosophically. It’s a tradition that goes back to the Institute’s founder,
Sidney Farber, MD, who conceived of a facility where scientists in upper-floor laboratories would make discoveries that could be used in treating cancer patients in ground-floor
clinics. Dr. Farber first saw his dream realized with the construction of the Jimmy Fund Building in 1951.
Dynamic exchanges between physicians and scientists
The tradition continues today with Dana-Farber’s home for patient care and clinical research, the
Yawkey Center for Cancer Care, which stands next to the Richard A. and Susan F. Smith Research Laboratories. These buildings are connected via enclosed
bridges containing meeting areas to foster dynamic exchanges between physicians and scientists.
The proximity of these facilities means that, in the everyday process of going to and from work or visiting colleagues elsewhere in the Institute, wet and dry laboratory-based scientists routinely encounter the ultimate beneficiaries of their efforts
— our patients and their families. The interconnectedness of the scientific and clinical worlds at Dana-Farber is also reflected in the Institute’s finances, where the amount spent on research is roughly equivalent to that spent on patient care.
Scientific work at Dana-Farber is based on the premise that basic and clinical investigation are complementary and reinforcing activities — and that drawing a strict demarcation between them creates a false distinction. Insights from one area invariably
inform and invigorate the other. To encourage this cross-pollination of ideas, the Institute has developed an organizational framework that fosters collaborations among investigators from different disciplines.
Commitment to pure science
The same attention to the underlying conditions that lead to outstanding research applies to the Institute’s support of "pure science." Research undertaken to answer basic biological questions, while recognizing the inherent value of empirical efforts
to expand knowledge, requires an environment in which free, interest-fueled inquiry is encouraged. Dana-Farber’s success in creating such an environment is reflected in the countless advances in the understanding of cellular and systemic processes
that have occurred in our laboratories. The commitment to curiosity-driven research remains undiminished even as the Institute integrates basic, translational, clinical, and population sciences research into a well-functioning transmission system
for scientific progress against cancer.
Dana-Farber’s strategic investment in research is realized through creating a cadre of established scientific leaders and talented young investigators, acquiring technology at the leading edge of cancer research, encouraging collaboration among the faculty,
providing resources in support of promising work, and ensuring a presiding spirit of innovation, which is the Institute’s legacy. The result is an intense scientific impact on a group of diseases that continue to represent one of humanity’s greatest
What most distinguishes Dana-Farber’s science, perhaps, is the preeminence of our investigators and the extent of their collaborations. Dana-Farber's scientific community includes nationally recognized leaders in fields across the spectrum of cancer research,
including dozens of scientific journals and cancer textbooks, Howard Hughes Medical Institute investigators, officers of professional associations, and authors of some of the most often-cited research papers of the past decade. Others are scientific
advisors to advocacy organizations, featured speakers at scientific conferences around the world, award-winning mentors, and elected members of professional organizations, including the National Academy of Sciences, the American Academy of Arts and
Sciences, and the Institute of Medicine.
A key index of scientific stature is Dana-Farber’s success in external peer-reviewed funding. The Institute continues to be one of the highest recipients of grant funding from the National Cancer Institute, an accomplishment that is particularly impressive
considering our relatively small faculty base. Moreover, Dana-Farber scientists compete successfully for grants from such noted foundations as the
Leukemia and Lymphoma Society,
American Cancer Society,
Bill and Melinda Gates Foundation,
Susan G. Komen for the Cure,
Doris Duke Charitable Foundation, Tisch Family Foundation, and
Robert Wood Johnson Foundation.
Leadership in clinical trials
Dana-Farber also has one of the largest cancer clinical trials programs in the country, with over 1,100 clinical trials. Importantly, more than one-quarter of these studies are investigator-initiated and
one-third are Phase I or I/II, demonstrating our commitment to translate basic research findings to the clinic through proof-of-principle and early phase studies.
The achievements of our faculty are in part due to a special environment, where collaboration is intrinsic to the way Dana-Farber researchers work. Tangible evidence of this is the number of NIH Specialized Projects of Research Excellence (SPORE) grants
and Program Project Grants awarded to Dana-Farber. It is the responsibility of the Institute’s Chief Scientific Officer,
Barrett J. Rollins, MD, PhD, to develop the tools and resources that Dana-Farber’s faculty need to realize their research vision, and to provide an environment that
supports and rewards collaboration.
This invigorating environment is furthered through scientific partnerships with other research centers. The most significant of these is
Dana-Farber/Harvard Cancer Center (DF/HCC), the largest NCI-designated Comprehensive Cancer Center in
the country. DF/HCC comprises more than 1,000 cancer researchers at Dana-Farber and six other Harvard-affiliated institutions who are working together with a singular goal — to find new and innovative ways to combat cancer. A related collaboration
has been established between scientists at DF/HCC and the University of Massachusetts Boston (UMB). The UMB-DF/HCC Comprehensive Cancer Partnership Program enhances research in health disparities and improves research, training, and outreach opportunities
for minority students, fellows, and scientists.
In addition, Dana-Farber faculty access resources and scientific expertise in highly specialized fields through the Institute’s associations with the Harvard Stem Cell Institute, Harvard’s NIH Clinical and Translational Science Center, and the Broad Institute,
a center of genomic research where several Dana-Farber faculty members have joint appointments. Established partnerships with pharmaceutical manufacturers have facilitated the development of new cancer drugs. Lastly, faculty enjoy the robust clinical
care, clinical research, and training opportunities made possible through long-standing hospital alliances, including
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Dana-Farber/Brigham and Women’s Cancer Center, and Dana-Farber/Partners CancerCare.
The forward-looking nature of research at Dana-Farber is embodied in the Institute’s commitment to developing the next generation of cancer science leaders. Dana-Farber faculty are recognized for their excellence in medical education, research training,
and clinical training. At
Harvard Medical School,
Harvard School of Public Health, and
Harvard College, our researchers teach graduate and undergraduate courses in basic biomedical and related sciences. They also serve as mentors for predoctoral
and postdoctoral trainees at Harvard and Harvard-affiliated institutions.
Building upon a determination to increase the pipeline of future cancer researchers, the Institute supports training programs with high schools, colleges, and community groups that enable underserved students to work in Dana-Farber laboratories and begin
their careers in science. Our adult and pediatric oncology fellowship programs, operated in conjunction with
Boston Children’s Hospital,
Brigham and Women’s Hospital, and
Massachusetts General Hospital, are among the most sought-after opportunities for aspiring cancer physician-scientists.
The combination of careful mentoring and encouragement of novel research projects has produced a corps of graduates who today are principal investigators and institutional leaders at cancer centers around the world. This same blend of opportunity and
guidance has spurred the careers of countless scientists who trained at Dana-Farber as postdoctoral fellows and graduate students.
Ultimately, Dana-Farber’s support of the scientific enterprise is driven by strategic thinking and ground-level pragmatics. We have acquired the capabilities to answer the next generation of questions in cancer research. The unrivaled combination of resources
and expertise available to Dana-Farber researchers ensures that the Institute will continue to lead for years to come.